STORM Therapeutics to Present Data on its First-in-Class MET

Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024 26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for...

Related Keywords

San Diego , California , United States , Babraham , Cambridgeshire , United Kingdom , Cambridge , American , Sarah Bucknell , Osian Evans , Eliza Yankova , Aleksandra Azevedo , Richard Fosbeary , Alexandra Sapetschnig , Harry Fischl , Jack Rogan , Natalie Webster , Matthew Fyfe , Beth Thomas , Oliver Rausch , Byron Andrews , Konstantinos Tzelepis , Group Leader , Storm Therapeutics Ltd , Cancer Research , Jeffrey Cheah Biomedical Centre , Cambridge Stem Cell Institute , Therapeutics Ltd , University Of Cambridge , American Association For Cancer Research , Babraham Research Campus , American Association , Annual Meeting , Chief Scientific Officer , Late Breaking Research , Molecular Therapeutics , Monday Apr , Poster Section , Board Number , Presentation Number , Stem Cell Institute , Puddicombe Way ,